Doxorubicin liposomal - Ambrilia Biopharma

Drug Profile

Doxorubicin liposomal - Ambrilia Biopharma

Alternative Names: TVT-Dox

Latest Information Update: 26 Jul 2013

Price : $50

At a glance

  • Originator Ambrilia Biopharma
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 26 Jul 2013 Discontinued - Preclinical for Cancer in Canada (Injection) prior to 26 July 2013
  • 07 Nov 2007 Data presented at the 19th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2007) added to the Cancer pharmacodynamics section
  • 03 Mar 2006 Cellpep has merged with Procyon Biopharma to form Ambrilia Biopharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top